Read by QxMD icon Read


Gregory S Phillips, Azael Freites-Martinez, Meier Hsu, Anna Skripnik Lucas, Dulce M Barrios, Kathryn Ciccolini, Michael A Marchetti, Liang Deng, Patricia L Myskowski, Erica H Lee, Alina Markova, Mario E Lacouture
BACKGROUND: Dermatologic conditions cause morbidity and mortality among hospitalized cancer patients. An improved understanding is critical for implementing clinical and research programs in inpatient oncodermatology. OBJECTIVE: To characterize inpatient dermatology consultations at a large comprehensive cancer center. METHODS: Retrospective database query of new admissions and medical record review of initial inpatient dermatology consultations comparing inpatients consulted and not consulted during January-December 2015...
December 19, 2017: Journal of the American Academy of Dermatology
C Lebbé
This 'What's new in oncodermatology?' addresses the developments in 2017 on the epidemiology and management of skin cancers. We observe a constant increase in carcinomas, risk factors for squamous cell carcinoma, especially in transplant recipients where skin cancer mortality is important. Among epidemiological developments in melanoma are increased mortality despite screening, occupational exposure to UV, second melanoma and higher risk after carcinoma. New classifications that should be considered are AJCC8 for melanoma and carcinoma...
December 2017: Annales de Dermatologie et de Vénéréologie
Anna Skripnik Lucas, Kathryn Ciccolini
OBJECTIVE: To review the emerging sub-specialty of oncodermatology and the role of oncodermatology nurses as facilitators of interprofessional collaboration between the oncology team and the dermatology team. DATA SOURCES: Journal articles indexed on the National Library of Medicine database. CONCLUSION: The complexity of cancer care with new cancer therapies and their associated dermatologic adverse events profiles benefit from a collaborative, interprofessional approach between dermatology and oncology in the care of the patient with cancer...
November 2017: Seminars in Oncology Nursing
Julia D Ransohoff, Bernice Y Kwong
The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. In this article we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies...
December 2017: Clinical Lymphoma, Myeloma & Leukemia
Sharon Baum, Aviv Barzilai
Modern dermatology is a reflection of the advances achieved in the general medical world. Thus, in recent years, dermatology encompasses many different fields and consequently, various subspecialties were created. In addition to dermatopathology and dermatosurgery, which are formal subspecialties, other fields of expertise include: autoimmune diseases, especially bullous diseases, hair and nail disorders, allergic diseases, infectious diseases and pigmented lesion clinics and oncodermatology. This current issue of "Harefuah" incorporates research and review articles from experts of the different subspecialties mentioned...
October 2016: Harefuah
Florian Herms, Nora Kramkimel, Elodie Regnier-Rosencher, Agnès Carlotti, Johan Chanal, Françoise Boitier, Selim Aractingi, Nicolas Dupin, Marie-Françoise Avril
Cutaneous squamous cell carcinoma (cSCC) is a frequent side-effect of vemurafenib treatment. The main aim of this study was to identify the clinical risk factors associated with the development of cSCC in melanoma patients treated with vemurafenib. We carried out a retrospective study, including 63 consecutive melanoma patients treated with vemurafenib for BRAF-mutant metastatic melanoma in an oncodermatological department. Clinical and follow-up data were collected and analysed, and a comparison of the subgroups who did and did not develop cSCC was performed...
October 2016: Melanoma Research
Adilson Costa, Michael Yi Bonner, Jack L Arbiser
Polyphenols are a widely used class of compounds in dermatology. While phenol itself, the most basic member of the phenol family, is chemically synthesized, most polyphenolic compounds are found in plants and form part of their defense mechanism against decomposition. Polyphenolic compounds, which include phenolic acids, flavonoids, stilbenes, and lignans, play an integral role in preventing the attack on plants by bacteria and fungi, as well as serving as cross-links in plant polymers. There is also mounting evidence that polyphenolic compounds play an important role in human health as well...
August 2016: American Journal of Clinical Dermatology
Veronika Tóth
The prevention and the early diagnosis of melanoma malignum are essential because of the aggressive spreading and poor therapeutic response of the tumor. Since survival mainly depends on the tumor stage, in the first part of the Ph.D. thesis the stage distribution of melanomas was assessed in the melanoma patients treated at the Department of Dermatology, Dermatooncology and Venerology, Semmelweis University. This work filled a gap, because the Hungarian National Cancer Registry, similarly to other cancer registries, does not include the tumor stages...
March 2, 2016: Magyar Onkologia
N Meyer
Oncodermatology is the topic of constant innovation since 5 years. These innovations have drammatically modified the prognostic of skin cancers and induced a change in the paradigm that drives the whole oncology. Once again in 2015, melanoma is the key topic of scientific communication, with promising results. However, unmet clinical needs must be kept in light. Some diseases, such as squamous cell carcinoma or cutaneous lymphoma remain poorly evaluated. This article was designed as a review of litterature...
December 2015: Annales de Dermatologie et de Vénéréologie
A Servy, N Kramkimel, N Franck, S Park, Y M Kirova
Helical tomotherapy is a recent modality of intensity-modulated, rotational irradiation being developed for treatment of an increasing number of malignancies. It allows delivering an accurate treatment while sparing critical organs thus optimizing the therapeutic ratio. In particular, it allows treating some tumour locations that could not be efficiently irradiated through more conventional irradiation devices. We report the usefulness of this approach for the treatment of complex lesions such as circumferential cutaneous lymphoma of the trunk...
March 2014: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
N Basset-Seguin
INTRODUCTION: Photodynamic therapy (PDT) combines the use of a topical sensitizer and its excitation with a light of appropriate wavelength. Its use in dermatooncology has been possible in France in 2006 when the methyl ester ALA or Metvixia® got approved. OBJECTIVE: To provide a panoramic view of validated indications of PDT in oncodermatology. METHOD: This work is based on the review of the literature as well as available guidelines or recommendation on PDT in dermatology...
November 2013: Annales de Dermatologie et de Vénéréologie
K Bustamante
No abstract text is available yet for this article.
April 2012: Annales de Chirurgie Plastique et Esthétique
B Chaput, S Le Guellec, M Courtade-Saïdi, D Gangloff, T Meresse, J-P Chavoin, J-L Grolleau, I Garrido
The skin oncology or "oncodermatology" requires a surgical treatment in most cases. For some surgeons, the oncodermatology takes a very important part of their practice. In the course of diagnostic and therapeutic of skin lesions, the pathologist plays now an essential role. He will guide our surgery. The techniques used by this specialist are numerous. Therefore, the objective of this paper is to review the different histological methods used to improve our management of skin tumors.
April 2012: Annales de Chirurgie Plastique et Esthétique
V Sibaud, J-P Delord, C Chevreau, D Gangloff, I Garrido-Stowhas
The management of oncology patients has been deeply modified over recent years by the development of new targeted anticancer therapies. Though these new therapies generally have a good safety profile, the skin is probably the organ most affected by their toxicity, in terms of frequency and symptom diversity. This review describes the most frequent cutaneous side effects induced by the new targeted therapies used in oncodermatology, whether they are well-established drugs such as EGF receptor inhibitors (cetuximab, erlotinib) or imatinib, or new treatments for metastatic melanoma such as selective BRAF (vemurafenib) or MEK inhibitors (selumetinib) and CTLA-4 monoclonal antibodies (ipilimumab)...
April 2012: Annales de Chirurgie Plastique et Esthétique
Yevgeniy Balagula, Steven T Rosen, Mario E Lacouture
Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments...
September 2011: Journal of the American Academy of Dermatology
L Mortier
During this year 2010, Oncodermatology was again the object of numerous publications. From the analysis of articles published between October 2009 and October 2010, choices had to be made. Overall, update on skin cancer has been dominated this year by breakthroughs on melanoma, which blows a wind of hope raised by the results of several clinical trials. Among those, it could be shown for the first time that a molecule was able to increase the overall survival of our patients (Ipilimumab). Spectacular results have also been obtained using anti-RAF...
December 2010: Annales de Dermatologie et de Vénéréologie
Th Passeron
Dermatology research has been very rich this year, once again. The physiopathological mechanisms of paradoxical reactions to anti-TNF are better understood and new therapeutic targets for psoriasis have been evidenced. Targeted therapy in oncodermatology have shown their potential usefulness clinically but fundamental data have also clarified their mechanisms of action as well as their limits. The key role played by the immune system in nonsegmental vitiligo has also been clearly demonstrated. Fibroblasts as well as visible light seem to play a key role that has been poorly understood to date within the complex mechanisms of cutaneous pigmentation...
December 2010: Annales de Dermatologie et de Vénéréologie
M Bagot
Several epidemiologic studies using the Surveillance, Epidemiology and End results program, have shown that the incidence of melanoma and of cutaneous lymphomas has clearly increased in the United States. Two independent groups have reported genome-wide association studies identifying variants associated to an increased risk of melanoma. Tumor stem cells were found to have an increased frequency when compared to previously reported studies, and also a greater plasticity. The Merkel cell polyoma virus seems rather ubiquitous, since it has been evidenced, without clonal integration, in several other types of cutaneous tumors, and even in healthy skin, with an increased frequency in photo-exposed skin and in immunodepressed patients...
December 2009: Annales de Dermatologie et de Vénéréologie
C Robert
News in the oncodermatology field this year were dominated by publications treating of melanoma and concerning in particular our increased knowledge of the various biological pathways involved in the distinct subtypes of melanoma. This molecular diversity is probably one of the reasons explaining the poor results of most of the clinical trials recently published because we don't know yet how to identify and select the right population of patients who could beneficiate from such or such therapy. However, some very encouraging results obtained with new protocols for adoptive immunotherapy have been published and we also hope that further results will confirm that the subset of KIT-mutated melanomas will beneficiate from an efficient targeted anti-Kit therapy...
December 2008: Annales de Dermatologie et de Vénéréologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"